Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5658 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 21 22 23 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Sigma-Aldrich–United States (govt): reference materials, 201506– collab with NIST to develop SRMs for qNMR 2015-06-04
Sigma-Aldrich–United States (govt): reference materials, 201506– distribution ww of NIST SRMs by Sigma-Aldrich 2015-06-04
MyoPowers–Alize RP: public relations, 201506 service existent by Alize RP 2015-06-03
MyoPowers–SEVERAL: investment, 201506 financing round €4.5m with returning investors Truffle Capital + Novartis Venture Fund + Gran Plasa 2015-06-03
Qurient–Max Planck: kinase inhibitor, 201506– license ww excl to CDK7 inhibitors from LDC + start of broader collaboration 2015-06-03
Guangzhou Bairui Medicine–BIA Separations: chromatography column, 201506– distribution of CIM columns by Bairui in China 2015-06-02
Bruker Corp–HighRes Biosolutions: lab automation technology, 201506 collab product integration HighRes robotics + s/w with Bruker autoflex speed MS 2015-06-01
Cevec–MC Services: public relations, 201506 service existent by MC Services AG 2015-06-01
EYE-RISK project–Ayoxxa: biomarker discovery, 201506–2019 Ayoxxa is industry partner in Horizon 2020 project to study factors for developing AMD 2015-06-01
EYE-RISK project–EU (govt): grant, 201506–2019 Horizon 2020 grant €6m to study factors for developing AMD 2015-06-01
Helmholtz–Bruker Corp: mass spectrometer, 201506 supply existent MALDI Tissuetyper Axel Walch at Helmholtz-Center in Munich is among early users 2015-06-01
Immuno-Transporter project–Germany (govt): grant, 201506– BMBF grant funding €3.8m over 3 years to develop cancer-immunotherapies 2015-06-01
LabCorp–Sysmex: molecular diagnostics, 201506– strategic alliance of Sysmex Inostics + Covance to support personalised drug developm 2015-06-01
MVZ Dortmund–Bruker Corp: mass spectrometer, 201506 supply existent use of MALDI Biotyper by MVZ Dortmund Dr Eberhard + Partner 2015-06-01
PRECIOUS project–CTC North: clinical research, 201506–202006 CTC North GmbH & Co KG is partner in Horizon 2020 project on stroke in elderly patients 2015-06-01
PRECIOUS project–EU (govt): grant, 201506–202006 Horizon 2020 grant €6m = total project cost co-ordinated by UMC Utrecht 2015-06-01
PRECIOUS project–Univ Hamburg: clinical research, 201506–202006 UKE is partner in Horizon 2020 project on stroke in elderly patients 2015-06-01
SeedWorks India–Bayer: investment, 201506 acquisition €na by Bayer CropScience 2015-06-01
Thermo Fisher–Univ Wisconsin: mass spectrometry, –201506 collab development of Q Exactive GC hybrid TQ-Orbitrap GC-/MS/MS system with Coon lab 2015-06-01
UCT Prague–Thermo Fisher: mass spectrometer, 201506 supply Q Exactive GC hybrid TQ-Orbitrap GC-/MS/MS Jana Hajslova is early user 2015-06-01
Univ Maastricht–Bruker Corp: mass spectrometer, 201506 supply existent MALDI Tissuetyper Ron Heeren at M4I Institute is among early users 2015-06-01
Univ Wisconsin–Thermo Fisher: mass spectrometer, 201506 supply Q Exactive GC hybrid TQ-Orbitrap GC-/MS/MS system Joshua Coon is early user 2015-06-01
Boehringer–Univ Michigan: drug discovery, 201505– collab research €na to discover new drugs for diabetic nephropathy 2015-05-28
Galenica–Roche: erythropoietin stimulating agent, 201505– license €na excl commercialisation of Mircera in US by Galenica + supply by Roche 2015-05-28
OTHER–AMP Biosimilars: biopharmaceutical, 201505– license for biogeneric ABY-018 in China to mid-sized Chinese pharma company 2015-05-28
TEMIS–Expert System: investment, 201505– acquisition ANNOUNCED 2015-05-28
Juno Therapeutics–Editas Medicine: cancer immunotherapy, 201505– strategic alliance to develop CAR-T + engineered TCR therapies 2015-05-27
Boehringer–Eureka Therapeutics: antibody cancer drug, 201505– collab drug discovery €na 2015-05-21
Biomay–VTU: recombinant protein production, 201505– license to Pichia pastoris protein expression technology to produce rec allergens 2015-05-20
Merus–EU (govt): grant, 201505– Eureka Eurostars grant totalling €2.1m for Merus + Selexis to develop bispecific antibody drugs for colorectal cancer 2015-05-20
Merus–Selexis: antibody cancer drug, 201505– collab combining Oligoclonics + SUREtechnology to develop bispecific antibody drugs for colorectal cancer 2015-05-20
Selexis–EU (govt): grant, 201505– Eureka Eurostars grant totalling €2.1m for Merus + Selexis to develop bispecific colorectal cancer antibody drugs 2015-05-20
Curasan–SEVERAL: investment, 201505 capital increase €1m with 730k new shares at €1.4/share 2015-05-19
Forbion–Germany (govt): investment, 201505 KfW invests into FCF III life science fund with new ERP VC Fund Investments 2015-05-19
Genmab–BioNTech: cancer immunotherapy, 201505– collab $10m upfront fee developm + commercialisation bispecific antibodies 2015-05-19
OctreoPharm–Ipsen: investment, 201505 acquisition 100% by Ipsen for up to €50m incl an upfront payment + milestones 2015-05-19
SVA Ltd–SGS: investment, 201505 acquisition by SGS 2015-05-19
Boehringer–Pharmaxis: SSAO/VAP-1 inhibitors, 201505 acquistion global rights €27.5m upfront + milestones to PXS4728A + related compounds by BI 2015-05-18
Comprehensive Biomarker Center–Agilent: microarray technology, 201505 supply existent CBC is Agilent Certified Microarray Service Provider 2015-05-15
Medi Analytika India–BIA Separations: chromatography, 201505– distribution of CIM monolyth columns in India by Medi Analytika 2015-05-15
Novartis–BioQuiddity: pharmaceutical, 201505– excl license + supply for ready-to-use ropivacaine + proponal infusions to Sandoz in US 2015-05-13
BioNTech–Hume Brophy: public relations, 201505 service existent by Hume Brophy 2015-05-11
BioNTech–Lilly: investment, 201505 equity investment $30m in BioNTech Cell & Gene Therapies GmbH as part of collab 2015-05-11
Epigenomics–SEVERAL: investment, 201505 capital increase €5m placing 976.6k new shares at €5.12 to existing shareholders 2015-05-11
Lilly–BioNTech: cancer immunotherapy, 201505– research collab $30m upfront + $300m milestones + royalties 2015-05-11
Stage Cell Therapeutics–Juno Therapeutics: investment, 201505 acquisition remaining 95% for €52.5m cash upfront + 486.3k shares + €135m milestones 2015-05-11
Cytos Biotechnology–SEVERAL: investment, 201505 conversion of all outstanding convertible bonds into 77.49m new shares making Cytos debt free 2015-05-08
Lanthio Pharma–MorphoSys: investment, 201505 acquisition of remaining 80% of shares for €20m from other investors by MorphoSys AG 2015-05-07
Nikon–Lonza: cell/gene therapy manufacturing, 201505– collab techn transfer + consulting for new Nikon plant in Japan 2015-05-07
Themis Bioscience–Omnes Capital: investment, 201505 financing round Series B 1st closing totalling €7m incl existing investor Omnes 2015-05-05
Themis Bioscience–SEVERAL: investment, 201505 financing round Series B €10m 1st closing €7m led by Wellington Partners 2015-05-05
Themis Bioscience–Ventech: investment, 201505 financing round Series B 1st closing totalling €7m incl existing investor Ventech 2015-05-05
Themis Bioscience–Wellington Partners: investment, 201505 financing round Series B 1st closing totalling €7m incl new + led investor Wellington 2015-05-05
Affimed–SEVERAL: investment, 201505 public offering $41.1m net $37.1m with 5m+750k common shares at $7.15/share 2015-05-04
Bayer–Isis Pharmaceuticals: factor XI inhibitor, 201505– license excl $100m upfront + milestones + tired royalties to ISIS-FXIRx 2015-05-04
Cambridge Bioscience–Genetrix (ES): genomic reagents, 201505– distribution non-excl Sygnis TruePrime + SunScript RT products in UK + IE 2015-05-04
Arcus Biosciences–Novartis: investment, 201505 financing round Series A totalling $49.7m incl co-investor Novartis 2015-05-01
Arcus Biosciences–SEVERAL: investment, 201505 financing round Series A $49.7m incl F&F + Column Group + Foresite Capital + Novartis + Celgene 2015-05-01
Auris Medical–SEVERAL: investment, 201505 public offering $25m with 5.275m common shares at $4.75/share 2015-05-01
Cyclenium–Haplogen: virostatic agents, 201505– collab drug discovery small molecule macroycle inhibitors using CMRT technology 2015-05-01
Merck (DE)–Genea Biomedx: IVD technology, 201505– collab ww marketing rights €na for Gavi + Geri + Gems + future product lines for Merck Serono 2015-05-01
Strüngmann Group–Formycon: biosimilar, 201505– license ww excl to Eylea biosimilar FYB203 to Santo Holding GmbH 2015-05-01
Newron–SEVERAL: investment, 201504 capital increase CHF24.3m private placement 843k new shares at CHF28.8/share 2015-04-30
CRISPR Therapeutics–Abingworth: investment, 201504 financing round totalling Series A $35m + Series B $29m incl new investor Abingworth 2015-04-29
CRISPR Therapeutics–Celgene: investment, 201504 financing round totalling Series A $35m + Series B $29m incl strategic investor Celgene Corp 2015-04-29
CRISPR Therapeutics–GSK: investment, 201504 financing round totalling Series A $35m + Series B $29m incl strategic investor SR One 2015-04-29
CRISPR Therapeutics–New Enterprise Associates: investment, 201504 financing round totalling Series A $35m + Series B $29m incl new investor NEA 2015-04-29
CRISPR Therapeutics–SEVERAL: investment, 201504 financing round Series A $35m + Series B $29m from SR One + Celgene + NEA + Abingworth + Versant 2015-04-29
CRISPR Therapeutics–Versant Ventures: investment, 201504 financing round totalling Series A $35m + Series B $29m incl founding investor Versant 2015-04-29
Cytena–High-Tech Gründerfonds: investment, 201504 seed financing round totalling €1.1.m from HTGF + a private investor 2015-04-29
Cytena–SEVERAL: investment, 201504 seed financing round €1.1.m from HTGF + a private investor 2015-04-29
Epigenomics–EU (govt): grant, 201504– Horizon 2020 grant €2.77m to validate lung cancer biomarkers in blood plasma 2015-04-29
Facio Therapies–Evotec: drug discovery services, 201504– supply screening service €na to identify drug for muscular wasting disease FSHD 2015-04-29
Lunaphore–Redalpine: investment, 201504 financing round Series A totalling CHF2m inc lead investor Redalpine 2015-04-29
Lunaphore–SEVERAL: investment, 201504 financing round Series A CHF2m led by Redalpine plus private investors from CH + GB 2015-04-29
Novartis–PeptiDream: drug discovery technology, 201504– license non-excl for use of PDPS technology by Novartis 2015-04-29
Univ Utrecht–Bruker Corp: mass spectrometer, 201504 supply existent UMC Utrecht has beeen using MALDI Biotyper for years 2015-04-27
Biofrontera–SEVERAL: investment, 201504–201505 open offer + private placement €3.1m w 2.173m new shares at €2.3/share 2015-04-23
Indivumed–Sysmex: molecular diagnostics, 201504– excl distribution of OncoBEAM CLIA lab services in DACH region by IndivuTest GmbH 2015-04-22
Univ Oslo–Medigene: DC vaccine, 201504 collab existent compassionate use in academic clinical studies in solid tumours by Oslo Univ Hospital 2015-04-20
BioOutsource–Sartorius: investment, 201504 acquisition €na by Sartorius Stedim Biotech 2015-04-17
Formycon–SEVERAL: investment, 201504 capital increase €11.1m with 435.9k new shares at €25.5/share to instituional investors + family offices 2015-04-16
Omeicos–MacDougall Biomedical Communications: public relations, 201504 service existent by MacDougall 2015-04-15
Omeicos–SEVERAL: investment, 201504 financing round Series A €6.2m led by Vesalius Biocapital II 2015-04-15
Menarini–4SC: resminostat, 201504– collab license + developm €95m upfront + milestones + royalties for Asia-Pacific excl JP Menarini Asia-Pacific 2015-04-14
Boehringer–Hydra Biosciences: TRP inhibitors, 201504– collab drug discovery small-molecule TRP inhibitors for renal diseases 2015-04-13
CAPP Medical–Roche: investment, 201504 acquisition by Roche 2015-04-13
Accovion–Clinipace: investment, 201504 acquisition of Accovion from HeidelbergCapital + Creathor Venture + management 2015-04-10
Biofrontera–Maschmeyer Group: investment, 201404 DIVESTMENT Maschmeyer sells 1m remaining shares to existing institutional investors of Biofrontera 2015-04-08
Blueberry Therapeutics–SEVERAL: investment, 201504 financing round $1.75m from UK + Swiss investors 2015-04-08
Prothena–SEVERAL: investment, 201504 public offering $122.1m net $114.2m with 3.3m ordinary shares $37/share 2015-04-08
CRISPR Therapeutics–MacDougall Biomedical Communications: public relations, 201504 service existent by MacDougall 2015-04-07
Merck (DE)–Pfizer: cancer drug, 201504– co-promotion of Xalkori in US + CA + JP + FR + DE + IT + ES + GB by Merck 2015-04-07
Nabriva–SEVERAL: investment, 201504 financing round Series B 1st tranche $50m of total $120m Series B led by Vivo Capital + OrbiMed 2015-04-07
Wilex–SEVERAL: investment, 201504 capital increase €4.16m with 1.5m new shares €2.8/share 2015-04-07
BMS–Uniqure: gene therapy, 201504– collab strategic alliance to develop gene therapy for cardiovascular diseases 2015-04-06
Hichrom–BIA Separations: chromatography, 201504– distribution of CIM monolyth columns in UK by Hichrom Ltd 2015-04-06
AMP Biosimilars–MC Services: public relations, 201504 service existent by MC Services AG 2015-04-02
Caribou Biosciences–SEVERAL: investment, 201504 financing round Series A $11m incl Fidelity Biosciences + Novartis + Mission Bay Capital et al 2015-04-02
Basilea–Univ London: panRAF kinase inhibitors, 201504– license ww excl to oral panRAF kinase inhibitors from ICR + CRT + Wellcome Trust et al 2015-04-01
next pagenext page 1 2 3 ... 21 22 23 ... 55 56 57  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top